{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["diabetes", "dipeptidyl peptidase-4", "medicinal plants", "natural compounds"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34203048", "DateRevised": {"Year": "2024", "Month": "04", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "06", "Day": "20"}], "Language": ["eng"], "ELocationID": ["591", "10.3390/ph14060591"], "Journal": {"ISSN": "1424-8247", "JournalIssue": {"Volume": "14", "Issue": "6", "PubDate": {"Year": "2021", "Month": "Jun", "Day": "20"}}, "Title": "Pharmaceuticals (Basel, Switzerland)", "ISOAbbreviation": "Pharmaceuticals (Basel)"}, "ArticleTitle": "A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes.", "Abstract": {"AbstractText": ["Type 2 diabetes mellitus (T2DM) is an increasing global public health problem, and its prevalence is expected to rise in coming decades. Dipeptidyl peptidase-4 (DPP-4) is a therapeutic target for the management of T2DM, and its inhibitors prevent the degradation of glucose-dependent insulinotropic peptide and glucagon-like peptide 1, and thus, maintain their endogenous levels and lower blood glucose levels. Various medicinal plant extracts and isolated bioactive compounds exhibit DPP-4 inhibitory activity. In this review, we discussed different natural sources that have been shown to have anti-diabetic efficacy with a particular emphasis on DPP-4 inhibition. Furthermore, the effect of DPP-4 inhibition on pancreatic beta cell function, skeletal muscle function, and the glucose-lowering mechanisms were also discussed. We believe that scientists looking for novel compounds with therapeutic promise against T2DM will be able to develop antidiabetic drugs using these natural sources."]}, "AuthorList": [{"Identifier": ["0000-0002-7489-2393"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea."}, {"Identifier": [], "Affiliation": "Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea."}], "LastName": "Shaikh", "ForeName": "Sibhghatulla", "Initials": "S"}, {"Identifier": ["0000-0003-2496-0463"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea."}, {"Identifier": [], "Affiliation": "Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea."}], "LastName": "Lee", "ForeName": "Eun-Ju", "Initials": "EJ"}, {"Identifier": ["0000-0002-1095-8445"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea."}, {"Identifier": [], "Affiliation": "Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea."}], "LastName": "Ahmad", "ForeName": "Khurshid", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea."}, {"Identifier": [], "Affiliation": "Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea."}], "LastName": "Ahmad", "ForeName": "Syed-Sayeed", "Initials": "SS"}, {"Identifier": ["0000-0002-0375-8170"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea."}], "LastName": "Lim", "ForeName": "Jeong-Ho", "Initials": "JH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea."}, {"Identifier": [], "Affiliation": "Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea."}], "LastName": "Choi", "ForeName": "Inho", "Initials": "I"}], "GrantList": [{"GrantID": "2020R1A6A1A03044512", "Agency": "National Research Foundation of Korea", "Country": ""}, {"GrantID": "NRF-2021R1A2C2004177", "Agency": "National Research Foundation of Korea", "Country": ""}, {"GrantID": "NRF-2019R1C1C1006542", "Agency": "National Research Foundation of Korea", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceuticals (Basel)", "NlmUniqueID": "101238453", "ISSNLinking": "1424-8247"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Campbell R.K. Fate of the beta-cell in the pathophysiology of type 2 diabetes. J. Am. Pharm. Assoc. 2009;49:S10\u2013S15. doi: 10.1331/JAPhA.2009.09076.", "ArticleIdList": ["10.1331/JAPhA.2009.09076", "19801360"]}, {"Citation": "Surampudi P.N., John-Kalarickal J., Fonseca V.A. Emerging Concepts in the Pathophysiology of Type 2 Diabetes Mellitus. Mt. Sinai J. Med. A J. Transl. Pers. Med. 2009;76:216\u2013226. doi: 10.1002/msj.20113.", "ArticleIdList": ["10.1002/msj.20113", "19421965"]}, {"Citation": "Wild S., Roglic G., Green A., Sicree R., King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047\u20131053. doi: 10.2337/diacare.27.5.1047.", "ArticleIdList": ["10.2337/diacare.27.5.1047", "15111519"]}, {"Citation": "Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and Cancer: A consensus report. Diabetes Care. 2010;33:1674\u20131685. doi: 10.2337/dc10-0666.", "ArticleIdList": ["10.2337/dc10-0666", "PMC2890380", "20587728"]}, {"Citation": "Sozen T., Center A.P.A.E.E., Basaran N.C., Tinazli M., Ozisik L. Musculoskeletal problems in diabetes mellitus. Eur. J. Rheumatol. 2018;5:258\u2013265. doi: 10.5152/eurjrheum.2018.18044.", "ArticleIdList": ["10.5152/eurjrheum.2018.18044", "PMC6267753", "30388074"]}, {"Citation": "Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes. 2015;6:1246\u20131258. doi: 10.4239/wjd.v6.i13.1246.", "ArticleIdList": ["10.4239/wjd.v6.i13.1246", "PMC4600176", "26468341"]}, {"Citation": "Al-Atram A.A. A review of the bidirectional relationship between psychiatric disorders and diabetes mellitus. Neurosciences. 2018;23:91\u201396. doi: 10.17712/nsj.2018.2.20170132.", "ArticleIdList": ["10.17712/nsj.2018.2.20170132", "PMC8015449", "29664448"]}, {"Citation": "Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA. 2003;100:6825\u20136830. doi: 10.1073/pnas.0631828100.", "ArticleIdList": ["10.1073/pnas.0631828100", "PMC164531", "12748388"]}, {"Citation": "Marguet D., Baggio L., Kobayashi T., Bernard A.-M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA. 2000;97:6874\u20136879. doi: 10.1073/pnas.120069197.", "ArticleIdList": ["10.1073/pnas.120069197", "PMC18768", "10823914"]}, {"Citation": "Gianani R. Beta cell regeneration in human pancreas. Semin. Immunopathol. 2010;33:23\u201327. doi: 10.1007/s00281-010-0235-7.", "ArticleIdList": ["10.1007/s00281-010-0235-7", "21188381"]}, {"Citation": "Cerf M.E. Beta Cell Dysfunction and Insulin Resistance. Front. Endocrinol. 2013;4:37. doi: 10.3389/fendo.2013.00037.", "ArticleIdList": ["10.3389/fendo.2013.00037", "PMC3608918", "23542897"]}, {"Citation": "Saisho Y. \u03b2-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J. Diabetes. 2015;6:109\u2013124. doi: 10.4239/wjd.v6.i1.109.", "ArticleIdList": ["10.4239/wjd.v6.i1.109", "PMC4317303", "25685282"]}, {"Citation": "Kooti W., Farokhipour M., Asadzadeh Z., Ashtary-Larky D., Asadi-Samani M. The role of medicinal plants in the treatment of diabetes: A systematic review. Electron. Physician. 2016;8:1832\u20131842. doi: 10.19082/1832.", "ArticleIdList": ["10.19082/1832", "PMC4768936", "26955456"]}, {"Citation": "KAMESWARA R.B., Giri R., Kesavulu M., Apparao C. Herbal medicine: In the management of diabetes mellitus. Manphar Vaidya Patrika. 1997;1:33\u201335."}, {"Citation": "Chang C.L.T., Lin Y., Bartolome A.P., Chen Y.-C., Chiu S.-C., Yang W.-C. Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology, and Potential Application of Selected Plants and Compounds. Evid. Based Complement. Altern. Med. 2013;2013:1\u201333. doi: 10.1155/2013/378657.", "ArticleIdList": ["10.1155/2013/378657", "PMC3638592", "23662132"]}, {"Citation": "Gao Y., Zhang Y., Zhu J., Li B., Li Z., Zhu W., Shi J., Jia Q., Li Y. Recent progress in natural products as DPP-4 inhibitors. Futur. Med. Chem. 2015;7:1079\u20131089. doi: 10.4155/fmc.15.49.", "ArticleIdList": ["10.4155/fmc.15.49", "26062402"]}, {"Citation": "Fukasawa K.M., Sahara N., Harada M., Kondo Y., Nagatsu I. Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands. J. Histochem. Cytochem. 1981;29:337\u2013343. doi: 10.1177/29.3.6787113.", "ArticleIdList": ["10.1177/29.3.6787113", "6787113"]}, {"Citation": "Matteucci E., Giampietro O. Dipeptidyl peptidase-4 (CD26): Knowing the function before inhibiting the enzyme. Curr. Med. Chem. 2009;16:2943\u20132951. doi: 10.2174/092986709788803114.", "ArticleIdList": ["10.2174/092986709788803114", "19689275"]}, {"Citation": "Lee S.A., Kim Y.R., Yang E.J., Kwon E.J., Kim S.H., Kang S.H., Park D.B., Oh B.C., Kim J., Heo S.T., et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2013;98:2553\u20132561. doi: 10.1210/jc.2012-4288.", "ArticleIdList": ["10.1210/jc.2012-4288", "23539735"]}, {"Citation": "Seino Y., Fukushima M., Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J. Diabetes Investig. 2010;1:8\u201323. doi: 10.1111/j.2040-1124.2010.00022.x.", "ArticleIdList": ["10.1111/j.2040-1124.2010.00022.x", "PMC4020673", "24843404"]}, {"Citation": "Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitors: Therapeutics for type 2 diabetes and what else? J. Med. Chem. 2014;57:2197\u20132212. doi: 10.1021/jm400658e.", "ArticleIdList": ["10.1021/jm400658e", "24099035"]}, {"Citation": "Deacon C.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2020;16:642\u2013653. doi: 10.1038/s41574-020-0399-8.", "ArticleIdList": ["10.1038/s41574-020-0399-8", "32929230"]}, {"Citation": "Plosker G.L. Sitagliptin: A review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:223\u2013242. doi: 10.1007/s40265-013-0169-1.", "ArticleIdList": ["10.1007/s40265-013-0169-1", "24407560"]}, {"Citation": "Keating G.M. Vildagliptin: A review of its use in type 2 diabetes mellitus. Drugs. 2014;74:587\u2013610. doi: 10.1007/s40265-014-0199-3.", "ArticleIdList": ["10.1007/s40265-014-0199-3", "24638989"]}, {"Citation": "Dhillon S. Saxagliptin: A Review in Type 2 Diabetes. Drugs. 2015;75:1783\u20131796. doi: 10.1007/s40265-015-0473-z.", "ArticleIdList": ["10.1007/s40265-015-0473-z", "26403305"]}, {"Citation": "Keating G.M. Alogliptin: A review of its use in patients with type 2 diabetes mellitus. Drugs. 2015;75:777\u2013796. doi: 10.1007/s40265-015-0385-y.", "ArticleIdList": ["10.1007/s40265-015-0385-y", "25855222"]}, {"Citation": "Lajara R. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin. Pharmacother. 2012;13:2663\u20132671. doi: 10.1517/14656566.2012.741591.", "ArticleIdList": ["10.1517/14656566.2012.741591", "23137412"]}, {"Citation": "Nishio S., Abe M., Ito H. Anagliptin in the treatment of type 2 diabetes: Safety, efficacy, and patient acceptability. Diabetes Metab. Syndr. Obes. 2015;8:163\u2013171. doi: 10.2147/DMSO.S54679.", "ArticleIdList": ["10.2147/DMSO.S54679", "PMC4370682", "25834461"]}, {"Citation": "Kim S.H., Lee S.H., Yim H.J. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: First new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch. Pharmacal Res. 2013;36:1185\u20131188. doi: 10.1007/s12272-013-0171-x.", "ArticleIdList": ["10.1007/s12272-013-0171-x", "23771499"]}, {"Citation": "Scott L.J. Teneligliptin: A review in type 2 diabetes. Clin. Drug Investig. 2015;35:765\u2013772. doi: 10.1007/s40261-015-0348-9.", "ArticleIdList": ["10.1007/s40261-015-0348-9", "26475720"]}, {"Citation": "McCormack P.L. Evogliptin: First Global Approval. Drugs. 2015;75:2045\u20132049. doi: 10.1007/s40265-015-0496-5.", "ArticleIdList": ["10.1007/s40265-015-0496-5", "26541763"]}, {"Citation": "Biftu T., Sinha-Roy R., Chen P., Qian X., Feng D., Kuethe J.T., Scapin G., Gao Y.D., Yan Y., Krueger D., et al. Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J. Med. Chem. 2014;57:3205\u20133212. doi: 10.1021/jm401992e.", "ArticleIdList": ["10.1021/jm401992e", "24660890"]}, {"Citation": "Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin. Pharmacother. 2015;16:2539\u20132547. doi: 10.1517/14656566.2015.1099630.", "ArticleIdList": ["10.1517/14656566.2015.1099630", "26523434"]}, {"Citation": "Sharma R., Sun H., Piotrowski D.W., Ryder T.F., Doran S.D., Dai H., Prakash C. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrol idin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. Drug Metab. Dispos. 2012;40:2143\u20132161. doi: 10.1124/dmd.112.047316.", "ArticleIdList": ["10.1124/dmd.112.047316", "22896728"]}, {"Citation": "Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review. Diabetes Obes. Metab. 2011;13:7\u201318. doi: 10.1111/j.1463-1326.2010.01306.x.", "ArticleIdList": ["10.1111/j.1463-1326.2010.01306.x", "21114598"]}, {"Citation": "Meloni A.R., DeYoung M.B., Lowe C., Parkes D.G. GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: Mechanism and glucose dependence. Diabetes Obes. Metab. 2013;15:15\u201327. doi: 10.1111/j.1463-1326.2012.01663.x.", "ArticleIdList": ["10.1111/j.1463-1326.2012.01663.x", "PMC3556522", "22776039"]}, {"Citation": "Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.U., McIntosh C.H., Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates \u03b2-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741\u2013750. doi: 10.2337/diabetes.52.3.741.", "ArticleIdList": ["10.2337/diabetes.52.3.741", "12606516"]}, {"Citation": "Ahren B., Foley J.E. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: Focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;59:907\u2013917. doi: 10.1007/s00125-016-3899-2.", "ArticleIdList": ["10.1007/s00125-016-3899-2", "26894277"]}, {"Citation": "Argun-Kurum G., Kaya-Dagistanli F., Ozturk M. DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats. Pharmacol. Rep. 2019;71:721\u2013731. doi: 10.1016/j.pharep.2019.03.008.", "ArticleIdList": ["10.1016/j.pharep.2019.03.008", "31207434"]}, {"Citation": "Omar B.A., Liehua L., Yamada Y., Seino Y., Marchetti P., Ahren B. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia. 2014;57:1876\u20131883. doi: 10.1007/s00125-014-3299-4.", "ArticleIdList": ["10.1007/s00125-014-3299-4", "24939431"]}, {"Citation": "Bugliani M., Syed F., Paula F.M.M., Omar B.A., Suleiman M., Mossuto S., Grano F., Cardarelli F., Boggi U., Vistoli F., et al. DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes. Mol. Cell. Endocrinol. 2018;473:186\u2013193. doi: 10.1016/j.mce.2018.01.019.", "ArticleIdList": ["10.1016/j.mce.2018.01.019", "29409957"]}, {"Citation": "Nagamatsu S., Ohara-Imaizumi M., Nakamichi Y., Aoyagi K., Nishiwaki C. DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice beta cells. Biochem. Biophys. Res. Commun. 2011;412:556\u2013560. doi: 10.1016/j.bbrc.2011.07.119.", "ArticleIdList": ["10.1016/j.bbrc.2011.07.119", "21854759"]}, {"Citation": "Duttaroy A., Voelker F., Merriam K., Zhang X., Ren X., Subramanian K., Hughes T.E., Burkey B.F. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur. J. Pharmacol. 2011;650:703\u2013707. doi: 10.1016/j.ejphar.2010.10.062.", "ArticleIdList": ["10.1016/j.ejphar.2010.10.062", "21070766"]}, {"Citation": "Takeda Y., Fujita Y., Honjo J., Yanagimachi T., Sakagami H., Takiyama Y., Makino Y., Abiko A., Kieffer T.J., Haneda M. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia. 2012;55:404\u2013412. doi: 10.1007/s00125-011-2365-4.", "ArticleIdList": ["10.1007/s00125-011-2365-4", "22072158"]}, {"Citation": "Han S.J., Choi S.E., Kang Y., Jung J.G., Yi S.A., Kim H.J., Lee K.W., Kim D.J. Effect of sitagliptin plus metformin on beta-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. Diabetes Res. Clin. Pract. 2011;92:213\u2013222. doi: 10.1016/j.diabres.2011.01.016.", "ArticleIdList": ["10.1016/j.diabres.2011.01.016", "21345512"]}, {"Citation": "Shah P., Ardestani A., Dharmadhikari G., Laue S., Schumann D.M., Kerr-Conte J., Pattou F., Klein T., Maedler K. The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J. Clin. Endocrinol. Metab. 2013;98:E1163\u2013E1172. doi: 10.1210/jc.2013-1029.", "ArticleIdList": ["10.1210/jc.2013-1029", "23633194"]}, {"Citation": "Akarte A.S., Srinivasan B.P., Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates beta-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J. Diabetes Complicat. 2012;26:266\u2013274. doi: 10.1016/j.jdiacomp.2012.03.013.", "ArticleIdList": ["10.1016/j.jdiacomp.2012.03.013", "22626875"]}, {"Citation": "Tanaka S., Suzuki K., Aoki C., Niitani M., Kato K., Tomotsune T., Aso Y. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol. Ther. 2014;16:840\u2013845. doi: 10.1089/dia.2014.0095.", "ArticleIdList": ["10.1089/dia.2014.0095", "PMC4241879", "25144424"]}, {"Citation": "Mori Y., Taniguchi Y., Miyazaki S., Yokoyama J., Utsunomiya K. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol. Ther. 2013;15:237\u2013240. doi: 10.1089/dia.2012.0214.", "ArticleIdList": ["10.1089/dia.2012.0214", "23402316"]}, {"Citation": "Ishikawa-Tanaka T., Hosojima M., Kabasawa H., Kaseda R., Yasukawa R., Yata Y., Kuwahara S., Kono E., Takata T., Iino N., et al. Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study. Diabetes Ther. 2020;11:2845\u20132861. doi: 10.1007/s13300-020-00928-5.", "ArticleIdList": ["10.1007/s13300-020-00928-5", "PMC7644617", "33000383"]}, {"Citation": "Suzuki R., Eiki J.I., Moritoyo T., Furihata K., Wakana A., Ohta Y., Tokita S., Kadowaki T. Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naive Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2018;20:2274\u20132281. doi: 10.1111/dom.13364.", "ArticleIdList": ["10.1111/dom.13364", "29770541"]}, {"Citation": "Kim G., Oh S., Jin S.M., Hur K.Y., Kim J.H., Lee M.K. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. Expert Opin. Pharmacother. 2017;18:1179\u20131186. doi: 10.1080/14656566.2017.1353080.", "ArticleIdList": ["10.1080/14656566.2017.1353080", "28714741"]}, {"Citation": "Kwak S.H., Hwang Y.C., Won J.C., Bae J.C., Kim H.J., Suh S., Lee E.Y., Lee S., Kim S.Y., Kim J.H. Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study) Diabetes Obes. Metab. 2020;22:173\u2013181. doi: 10.1111/dom.13882.", "ArticleIdList": ["10.1111/dom.13882", "31502749"]}, {"Citation": "Cho K.Y., Nomoto H., Nakamura A., Kawata S., Sugawara H., Takeuchi J., Nagai S., Tsuchida K., Omori K., Yokoyama H., et al. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study) Diabetes Obes. Metab. 2020;22:458\u2013462. doi: 10.1111/dom.13879.", "ArticleIdList": ["10.1111/dom.13879", "PMC7065098", "31486230"]}, {"Citation": "Fuchigami A., Shigiyama F., Kitazawa T., Okada Y., Ichijo T., Higa M., Hiyoshi T., Inoue I., Iso K., Yoshii H., et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: A prospective, randomized study (DIVERSITY-CVR) Cardiovasc. Diabetol. 2020;19:1. doi: 10.1186/s12933-019-0977-z.", "ArticleIdList": ["10.1186/s12933-019-0977-z", "PMC6945792", "31910850"]}, {"Citation": "Lyu F.P., Huang B.K., Su W.J., Yan F.F., Zeng J.Y., Chen Z., Zhang Y.X., Wang S.H., Huang Y.X., Zhang M.L., et al. Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes. Diabetes Ther. 2020;11:701\u2013710. doi: 10.1007/s13300-020-00758-5.", "ArticleIdList": ["10.1007/s13300-020-00758-5", "PMC7048888", "32020552"]}, {"Citation": "Okajima F., Emoto N., Kato K., Sugihara H. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin. J. Atheroscler. Thromb. 2017;24:157\u2013168. doi: 10.5551/jat.32409.", "ArticleIdList": ["10.5551/jat.32409", "PMC5305676", "27397060"]}, {"Citation": "Ahren B., Foley J.E., Ferrannini E., Matthews D.R., Zinman B., Dejager S., Fonseca V.A. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33:730\u2013732. doi: 10.2337/dc09-1867.", "ArticleIdList": ["10.2337/dc09-1867", "PMC2845014", "20067974"]}, {"Citation": "Ahren B., Schweizer A., Dejager S., Dunning B.E., Nilsson P.M., Persson M., Foley J.E. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2009;94:1236\u20131243. doi: 10.1210/jc.2008-2152.", "ArticleIdList": ["10.1210/jc.2008-2152", "19174497"]}, {"Citation": "Li F.F., Shen Y., Sun R., Zhang D.F., Jin X., Zhai X.F., Chen M.Y., Su X.F., Wu J.D., Ye L., et al. Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes. Diabetes Ther. 2017;8:1111\u20131122. doi: 10.1007/s13300-017-0303-2.", "ArticleIdList": ["10.1007/s13300-017-0303-2", "PMC5630558", "28921310"]}, {"Citation": "Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148\u20131155. doi: 10.1007/s00125-007-0633-0.", "ArticleIdList": ["10.1007/s00125-007-0633-0", "17387446"]}, {"Citation": "Gupta R.C., Dettbarn W.-D., Milatovic D. Handbook of Toxicology of Chemical Warfare Agents. Elsevier; Amsterdam, The Netherlands: 2009. Skeletal Muscle; pp. 509\u2013531."}, {"Citation": "Kluess H.A. Dipeptidyl Peptidase IV as a Muscle Myokine. Front. Physiol. 2020;11:148. doi: 10.3389/fphys.2020.00148.", "ArticleIdList": ["10.3389/fphys.2020.00148", "PMC7063094", "32194435"]}, {"Citation": "Raschke S., Eckardt K., Bjorklund Holven K., Jensen J., Eckel J. Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS ONE. 2013;8:e62008. doi: 10.1371/journal.pone.0062008.", "ArticleIdList": ["10.1371/journal.pone.0062008", "PMC3634789", "23637948"]}, {"Citation": "Neidert L.E., Al-Tarhuni M., Goldman D., Kluess H.A., Jackson D.N. Endogenous dipeptidyl peptidase IV modulates skeletal muscle arteriolar diameter in rats. Physiol. Rep. 2018;6 doi: 10.14814/phy2.13564.", "ArticleIdList": ["10.14814/phy2.13564", "PMC5789721", "29380955"]}, {"Citation": "Bouchi R., Fukuda T., Takeuchi T., Nakano Y., Murakami M., Minami I., Izumiyama H., Hashimoto K., Yoshimoto T., Ogawa Y. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 2018;34 doi: 10.1002/dmrr.2957.", "ArticleIdList": ["10.1002/dmrr.2957", "29054111"]}, {"Citation": "Ishii S., Nagai Y., Kato H., Fukuda H., Tanaka Y. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes. J. Clin. Med. Res. 2020;12:122\u2013126. doi: 10.14740/jocmr4078.", "ArticleIdList": ["10.14740/jocmr4078", "PMC7011940", "32095182"]}, {"Citation": "Kalhotra P., Chittepu V.C.S.R., Osorio-Revilla G., Gallardo-Velazquez T. Chrysin in Combination with Insulin Promotes Glucose Uptake in Skeletal Muscle Cell: Impact of Combination Therapy in Diabetes Myopathy (P01-031-19) Curr. Dev. Nutr. 2019;3:nzz028-P01. doi: 10.1093/cdn/nzz028.P01-031-19.", "ArticleIdList": ["10.1093/cdn/nzz028.P01-031-19"]}, {"Citation": "Kalhotra P., Chittepu V., Osorio-Revilla G., Gallardo-Velazquez T. Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes. Int. J. Mol. Sci. 2019;20:1228. doi: 10.3390/ijms20051228.", "ArticleIdList": ["10.3390/ijms20051228", "PMC6429117", "30862104"]}, {"Citation": "Lalitha N., Sadashivaiah B., Ramaprasad T.R., Singh S.A. Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein. PLoS ONE. 2020;15:e0231543. doi: 10.1371/journal.pone.0231543.", "ArticleIdList": ["10.1371/journal.pone.0231543", "PMC7153899", "32282828"]}, {"Citation": "Lee E.J., Shaikh S., Ahmad K., Ahmad S.S., Lim J.H., Park S., Yang H.J., Cho W.K., Park S.J., Lee Y.H., et al. Isolation and Characterization of Compounds from Glycyrrhiza uralensis as Therapeutic Agents for the Muscle Disorders. Int. J. Mol. Sci. 2021;22:876. doi: 10.3390/ijms22020876.", "ArticleIdList": ["10.3390/ijms22020876", "PMC7830955", "33467209"]}, {"Citation": "Howes M.J.R., Quave C.L., Collemare J., Tatsis E.C., Twilley D., Lulekal E., Farlow A., Li L., Cazar M.E., Leaman D.J. Molecules from nature: Reconciling biodiversity conservation and global healthcare imperatives for sustainable use of medicinal plants and fungi. Plants People Planet. 2020;2:463\u2013481. doi: 10.1002/ppp3.10138.", "ArticleIdList": ["10.1002/ppp3.10138"]}, {"Citation": "Baig M.H., Jan A.T., Rabbani G., Ahmad K., Ashraf J.M., Kim T., Min H.S., Lee Y.H., Cho W.K., Ma J.Y., et al. Methylglyoxal and Advanced Glycation End products: Insight of the regulatory machinery affecting the myogenic program and of its modulation by natural compounds. Sci. Rep. 2017;7:5916. doi: 10.1038/s41598-017-06067-5.", "ArticleIdList": ["10.1038/s41598-017-06067-5", "PMC5517486", "28725008"]}, {"Citation": "Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 2014;4:177. doi: 10.3389/fphar.2013.00177.", "ArticleIdList": ["10.3389/fphar.2013.00177", "PMC3887317", "24454289"]}, {"Citation": "Onoagbe I., Negbenebor E., Ogbeide V., Dawha I., Attah V., Lau H., Omonkhua A. A study of the anti-diabetic effects of Urena lobata and Sphenostylis stenocarpa in streptozotocin-induced diabetic rats. Eur. J. Sci. Res. 2010;43:6\u201314."}, {"Citation": "Purnomo Y., Soeatmadji D.W., Sumitro S.B., Widodo M.A. Anti-diabetic potential of Urena lobata leaf extract through inhibition of dipeptidyl peptidase IV activity. Asian Pac. J. Trop. Biomed. 2015;5:645\u2013649. doi: 10.1016/j.apjtb.2015.05.014.", "ArticleIdList": ["10.1016/j.apjtb.2015.05.014"]}, {"Citation": "Ramachandran S., Faisal T.K., Anjumary J., Rajasekaran A., Asokkumar K., Annadurai K., Arivukkarasu R., Sharma R.K., Shankar M.B. Comparative evaluation of hypoglycemic and hypolipidemic activity of various extract of Anogeissus latifolia bark in streptozotocin-induced diabetic rats. J. Complement. Integr. Med. 2017;14 doi: 10.1515/jcim-2016-0130.", "ArticleIdList": ["10.1515/jcim-2016-0130", "28889731"]}, {"Citation": "Baliga M.S., Thilakchand K.R., Rai M.P., Rao S., Venkatesh P. Aegle marmelos (L.) Correa (Bael) and its phytochemicals in the treatment and prevention of cancer. Integr. Cancer Ther. 2013;12:187\u2013196. doi: 10.1177/1534735412451320.", "ArticleIdList": ["10.1177/1534735412451320", "23089553"]}, {"Citation": "Ansari P., Hannon-Fletcher M.P., Flatt P.R., Abdel-Wahab Y.H.A. Effects of 22 traditional anti-diabetic medicinal plants on DPP-IV enzyme activity and glucose homeostasis in high-fat fed obese diabetic rats. Biosci. Rep. 2021;41 doi: 10.1042/BSR20203824.", "ArticleIdList": ["10.1042/BSR20203824", "PMC7823188", "33416077"]}, {"Citation": "Bharti S.K., Krishnan S., Kumar A., Rajak K.K., Murari K., Bharti B.K., Gupta A.K. Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: Investigation by experimental validation and molecular docking. Phytomedicine. 2012;20:24\u201331. doi: 10.1016/j.phymed.2012.09.009.", "ArticleIdList": ["10.1016/j.phymed.2012.09.009", "23063145"]}, {"Citation": "Saleem S., Jafri L., Haq I.U., Chang L.C., Calderwood D., Green B.D., Mirza B. Plants Fagonia cretica L. and Hedera nepalensis K. Koch contain natural compounds with potent dipeptidyl peptidase-4 (DPP-4) inhibitory activity. J. Ethnopharmacol. 2014;156:26\u201332. doi: 10.1016/j.jep.2014.08.017.", "ArticleIdList": ["10.1016/j.jep.2014.08.017", "25169215"]}, {"Citation": "Kosaraju J., Dubala A., Chinni S., Khatwal R.B., Satish Kumar M.N., Basavan D. A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes. Pharm. Biol. 2014;52:268\u2013271. doi: 10.3109/13880209.2013.823550.", "ArticleIdList": ["10.3109/13880209.2013.823550", "24074231"]}, {"Citation": "Nongonierma A.B., Le Maux S., Dubrulle C., Barre C., FitzGerald R.J. Quinoa (Chenopodium quinoa Willd.) protein hydrolysates with in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory and antioxidant properties. J. Cereal Sci. 2015;65:112\u2013118. doi: 10.1016/j.jcs.2015.07.004.", "ArticleIdList": ["10.1016/j.jcs.2015.07.004"]}, {"Citation": "Bayan L., Koulivand P.H., Gorji A. Garlic: A review of potential therapeutic effects. Avicenna J. Phytomed. 2014;4:1\u201314.", "ArticleIdList": ["PMC4103721", "25050296"]}, {"Citation": "Kalhotra P., Chittepu V., Osorio-Revilla G., Gallardo-Velazquez T. Phytochemicals in Garlic Extract Inhibit Therapeutic Enzyme DPP-4 and Induce Skeletal Muscle Cell Proliferation: A Possible Mechanism of Action to Benefit the Treatment of Diabetes Mellitus. Biomolecules. 2020;10:305. doi: 10.3390/biom10020305.", "ArticleIdList": ["10.3390/biom10020305", "PMC7072494", "32075130"]}, {"Citation": "Bansal P., Paul P., Mudgal J., Nayak P.G., Pannakal S.T., Priyadarsini K.I., Unnikrishnan M.K. Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice. Exp. Toxicol. Pathol. 2012;64:651\u2013658. doi: 10.1016/j.etp.2010.12.009.", "ArticleIdList": ["10.1016/j.etp.2010.12.009", "21208790"]}, {"Citation": "Aderibigbe A.O., Emudianughe T.S., Lawal B.A. Evaluation of the antidiabetic action of Mangifera indica in mice. Phytother. Res. 2001;15:456\u2013458. doi: 10.1002/ptr.859.", "ArticleIdList": ["10.1002/ptr.859", "11507745"]}, {"Citation": "Yogisha S., Raveesha K.A. Dipeptidyl Peptidase IV inhibitory activity of Mangifera indica. J. Nat. Prod. 2010;3:9."}, {"Citation": "Suman R.K., Mohanty I.R., Maheshwari U., Borde M.K., Deshmukh Y.A. Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats. Diabetes Metab. Syndr. Obes. 2016;9:261\u2013272. doi: 10.2147/DMSO.S109599.", "ArticleIdList": ["10.2147/DMSO.S109599", "PMC5010077", "27621658"]}, {"Citation": "Kim B.R., Thapa P., Kim H.M., Jin C.H., Kim S.H., Kim J.B., Choi H., Han A.R., Nam J.W. Purification of Phenylpropanoids from the Scaly Bulbs of Lilium Longiflorum by CPC and Determination of Their DPP-IV Inhibitory Potentials. ACS Omega. 2020;5:4050\u20134057. doi: 10.1021/acsomega.9b03649.", "ArticleIdList": ["10.1021/acsomega.9b03649", "PMC7057705", "32149232"]}, {"Citation": "Kim B.R., Paudel S.B., Nam J.W., Jin C.H., Lee I.S., Han A.R. Constituents of Coreopsis lanceolata Flower and Their Dipeptidyl Peptidase IV Inhibitory Effects. Molecules. 2020;25:4370. doi: 10.3390/molecules25194370.", "ArticleIdList": ["10.3390/molecules25194370", "PMC7582822", "32977609"]}, {"Citation": "Eidenberger T., Selg M., Krennhuber K. Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (Psidium guajava L.): A key to the beneficial effects of guava in type II diabetes mellitus. Fitoterapia. 2013;89:74\u201379. doi: 10.1016/j.fitote.2013.05.015.", "ArticleIdList": ["10.1016/j.fitote.2013.05.015", "23707747"]}, {"Citation": "Quek A., Kassim N.K., Ismail A., Latif M.A.M., Shaari K., Tan D.C., Lim P.C. Identification of Dipeptidyl Peptidase-4 and alpha-Amylase Inhibitors from Melicope glabra (Blume) T. G. Hartley (Rutaceae) Using Liquid Chromatography Tandem Mass Spectrometry, In Vitro and In Silico Methods. Molecules. 2020;26:1. doi: 10.3390/molecules26010001.", "ArticleIdList": ["10.3390/molecules26010001", "PMC7792625", "33374962"]}, {"Citation": "Ansari P., Azam S., Hannan J.M.A., Flatt P.R., Abdel Wahab Y.H.A. Anti-hyperglycaemic activity of H. rosa-sinensis leaves is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of insulin secretion. J. Ethnopharmacol. 2020;253:112647. doi: 10.1016/j.jep.2020.112647.", "ArticleIdList": ["10.1016/j.jep.2020.112647", "32035878"]}, {"Citation": "Li W.L., Zheng H.C., Bukuru J., De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J. Ethnopharmacol. 2004;92:1\u201321. doi: 10.1016/j.jep.2003.12.031.", "ArticleIdList": ["10.1016/j.jep.2003.12.031", "15099842"]}, {"Citation": "Ansari P., Flatt P.R., Harriott P., Abdel-Wahab Y.H.A. Evaluation of the Antidiabetic and Insulin Releasing Effects of A. squamosa, Including Isolation and Characterization of Active Phytochemicals. Plants. 2020;9:1348. doi: 10.3390/plants9101348.", "ArticleIdList": ["10.3390/plants9101348", "PMC7601933", "33053901"]}, {"Citation": "Majeed M., Majeed S., Mundkur L., Nagabhushanam K., Arumugam S., Beede K., Ali F. Standardized Emblica officinalis fruit extract inhibited the activities of alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase-4 and displayed antioxidant potential. J. Sci. Food Agric. 2020;100:509\u2013516. doi: 10.1002/jsfa.10020.", "ArticleIdList": ["10.1002/jsfa.10020", "PMC6973029", "31487036"]}, {"Citation": "Chakrabarti R., Bhavtaran S., Narendra P., Varghese N., Vanchhawng L., Mohamed Sham Shihabudeen H., Thirumurgan K. Dipeptidyl peptidase-IV inhibitory activity of Berberis aristata. J. Nat. Prod. 2011;4:158\u2013163."}, {"Citation": "Wang F., Yu G., Zhang Y., Zhang B., Fan J. Dipeptidyl Peptidase IV Inhibitory Peptides Derived from Oat (Avena sativa L.), Buckwheat (Fagopyrum esculentum), and Highland Barley (Hordeum vulgare trifurcatum (L.) Trofim) Proteins. J. Agric. Food Chem. 2015;63:9543\u20139549. doi: 10.1021/acs.jafc.5b04016.", "ArticleIdList": ["10.1021/acs.jafc.5b04016", "26468909"]}, {"Citation": "Ekayanti M., Sauriasari R., Elya B. Dipeptidyl peptidase IV inhibitory activity of fraction from white tea ethanolic extract (Camellia sinensis (L.) Kuntze) ex vivo. Pharmacogn. J. 2018;10:190\u2013193. doi: 10.5530/pj.2018.1.32.", "ArticleIdList": ["10.5530/pj.2018.1.32"]}, {"Citation": "Lin Y.S., Chen C.R., Wu W.H., Wen C.L., Chang C.I., Hou W.C. Anti-alpha-glucosidase and Anti-dipeptidyl Peptidase-IV Activities of Extracts and Purified Compounds from Vitis thunbergii var. taiwaniana. J. Agric. Food Chem. 2015;63:6393\u20136401. doi: 10.1021/acs.jafc.5b02069.", "ArticleIdList": ["10.1021/acs.jafc.5b02069", "26138774"]}, {"Citation": "Kumar V., Sachan R., Rahman M., Sharma K., Al-Abbasi F.A., Anwar F. Prunus amygdalus extract exert antidiabetic effect via inhibition of DPP-IV: In-silico and in-vivo approaches. J. Biomol. Struct. Dyn. 2020:1\u201315. doi: 10.1080/07391102.2020.1775124.", "ArticleIdList": ["10.1080/07391102.2020.1775124", "32602806"]}, {"Citation": "YARIZADE A., KUMLEH H.H., Niazi A. In vitro antidiabetic effects of ferula assa-foetida extracts through dipeptidyl peptidase iv and \u03b1-glucosidase inhibitory activity. IN VITRO. 2017;10 doi: 10.22159/ajpcr.2017.v10i5.16648.", "ArticleIdList": ["10.22159/ajpcr.2017.v10i5.16648"]}, {"Citation": "Morikawa T., Ninomiya K., Akaki J., Kakihara N., Kuramoto H., Matsumoto Y., Hayakawa T., Muraoka O., Wang L.B., Wu L.J., et al. Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of Helichrysum arenarium. J. Nat. Med. 2015;69:494\u2013506. doi: 10.1007/s11418-015-0914-8.", "ArticleIdList": ["10.1007/s11418-015-0914-8", "PMC4703617", "25921859"]}, {"Citation": "Cragg G.M., Newman D.J. Natural products: A continuing source of novel drug leads. Biochim. Biophys. Acta. 2013;1830:3670\u20133695. doi: 10.1016/j.bbagen.2013.02.008.", "ArticleIdList": ["10.1016/j.bbagen.2013.02.008", "PMC3672862", "23428572"]}, {"Citation": "Al-masri I.M., Mohammad M.K., Tahaa M.O. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J. Enzym. Inhib. Med. Chem. 2009;24:1061\u20131066. doi: 10.1080/14756360802610761.", "ArticleIdList": ["10.1080/14756360802610761", "19640223"]}, {"Citation": "Fan J., Johnson M.H., Lila M.A., Yousef G., de Mejia E.G. Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management. Evid. Based Complement. Altern. Med. 2013;2013:479505. doi: 10.1155/2013/479505.", "ArticleIdList": ["10.1155/2013/479505", "PMC3773436", "24069048"]}, {"Citation": "C\u00e1sedas G., Les F., Gonz\u00e1lez-Burgos E., G\u00f3mez-Serranillos M.P., Smith C., L\u00f3pez V. Cyanidin-3-O-glucoside inhibits different enzymes involved in central nervous system pathologies and type-2 diabetes. S. Afr. J. Bot. 2019;120:241\u2013246. doi: 10.1016/j.sajb.2018.07.001.", "ArticleIdList": ["10.1016/j.sajb.2018.07.001"]}, {"Citation": "Wang Z., Yang L., Fan H., Wu P., Zhang F., Zhang C., Liu W., Li M. Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4. PeerJ. 2017;5:e3283. doi: 10.7717/peerj.3283.", "ArticleIdList": ["10.7717/peerj.3283", "PMC5428354", "28507818"]}, {"Citation": "Gupta A., Jacobson G.A., Burgess J.R., Jelinek H.F., Nichols D.S., Narkowicz C.K., Al-Aubaidy H.A. Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications. Biochem. Biophys. Res. Commun. 2018;503:21\u201325. doi: 10.1016/j.bbrc.2018.04.156.", "ArticleIdList": ["10.1016/j.bbrc.2018.04.156", "29698678"]}, {"Citation": "Parmar H.S., Jain P., Chauhan D.S., Bhinchar M.K., Munjal V., Yusuf M., Choube K., Tawani A., Tiwari V., Manivannan E., et al. DPP-IV inhibitory potential of naringin: An in silico, in vitro and in vivo study. Diabetes Res. Clin. Pract. 2012;97:105\u2013111. doi: 10.1016/j.diabres.2012.02.011.", "ArticleIdList": ["10.1016/j.diabres.2012.02.011", "22410395"]}, {"Citation": "Bower A.M., Real Hernandez L.M., Berhow M.A., de Mejia E.G. Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV. J. Agric. Food Chem. 2014;62:6147\u20136158. doi: 10.1021/jf500639f.", "ArticleIdList": ["10.1021/jf500639f", "24881464"]}, {"Citation": "Singh A.K., Patel P.K., Choudhary K., Joshi J., Yadav D., Jin J.O. Quercetin and Coumarin Inhibit Dipeptidyl Peptidase-IV and Exhibits Antioxidant Properties: In Silico, In Vitro, Ex Vivo. Biomolecules. 2020;10:207. doi: 10.3390/biom10020207.", "ArticleIdList": ["10.3390/biom10020207", "PMC7072504", "32023875"]}, {"Citation": "Zhang L., Zhang S.-T., Yin Y.-C., Xing S., Li W.-N., Fu X.-Q. Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic mice. RSC Adv. 2018;8:14967\u201314974. doi: 10.1039/C8RA00675J.", "ArticleIdList": ["10.1039/C8RA00675J", "PMC9080018", "35541310"]}, {"Citation": "Zhao B.T., Le D.D., Nguyen P.H., Ali M.Y., Choi J.S., Min B.S., Shin H.M., Rhee H.I., Woo M.H. PTP1B, alpha-glucosidase, and DPP-IV inhibitory effects for chromene derivatives from the leaves of Smilax china L. Chem. Biol. Interact. 2016;253:27\u201337. doi: 10.1016/j.cbi.2016.04.012.", "ArticleIdList": ["10.1016/j.cbi.2016.04.012", "27060210"]}, {"Citation": "Katkar K.V., Suthar A.C., Chauhan V.S. The chemistry, pharmacologic, and therapeutic applications of Polyalthia longifolia. Pharmacogn. Rev. 2010;4:62\u201368. doi: 10.4103/0973-7847.65329.", "ArticleIdList": ["10.4103/0973-7847.65329", "PMC3249904", "22228943"]}, {"Citation": "Huang P.K., Lin S.R., Riyaphan J., Fu Y.S., Weng C.F. Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4. Int. J. Mol. Sci. 2019;20:530. doi: 10.3390/ijms20030530.", "ArticleIdList": ["10.3390/ijms20030530", "PMC6387447", "30691220"]}, {"Citation": "Geng Y., Lu Z.M., Huang W., Xu H.Y., Shi J.S., Xu Z.H. Bioassay-guided isolation of DPP-4 inhibitory fractions from extracts of submerged cultured of Inonotus obliquus. Molecules. 2013;18:1150\u20131161. doi: 10.3390/molecules18011150.", "ArticleIdList": ["10.3390/molecules18011150", "PMC6270506", "23325103"]}, {"Citation": "Huang P.K., Lin S.R., Chang C.H., Tsai M.J., Lee D.N., Weng C.F. Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV. Sci. Rep. 2019;9:15585. doi: 10.1038/s41598-019-52088-7.", "ArticleIdList": ["10.1038/s41598-019-52088-7", "PMC6821704", "31666589"]}, {"Citation": "Kalhotra P., Chittepu V., Osorio-Revilla G., Gallardo-Velazquez T. Structure(-)Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study. Molecules. 2018;23:1368. doi: 10.3390/molecules23061368.", "ArticleIdList": ["10.3390/molecules23061368", "PMC6100528", "29882783"]}, {"Citation": "Kim B.R., Kim H.Y., Choi I., Kim J.B., Jin C.H., Han A.R. DPP-IV Inhibitory Potentials of Flavonol Glycosides Isolated from the Seeds of Lens culinaris: In Vitro and Molecular Docking Analyses. Molecules. 2018;23:1998. doi: 10.3390/molecules23081998.", "ArticleIdList": ["10.3390/molecules23081998", "PMC6222902", "30103438"]}, {"Citation": "Abdel Motaal A., Salem H.H., Almaghaslah D., Alsayari A., Bin Muhsinah A., Alfaifi M.Y., Elbehairi S.E.I., Shati A.A., El-Askary H. Flavonol Glycosides: In Vitro Inhibition of DPPIV, Aldose Reductase and Combating Oxidative Stress are Potential Mechanisms for Mediating the Antidiabetic Activity of Cleome droserifolia. Molecules. 2020;25:5864. doi: 10.3390/molecules25245864.", "ArticleIdList": ["10.3390/molecules25245864", "PMC7764826", "33322431"]}, {"Citation": "Mojica L., de Mejia E.G. Optimization of enzymatic production of anti-diabetic peptides from black bean (Phaseolus vulgaris L.) proteins, their characterization and biological potential. Food Funct. 2016;7:713\u2013727. doi: 10.1039/C5FO01204J.", "ArticleIdList": ["10.1039/C5FO01204J", "26824775"]}, {"Citation": "Mojica L., Luna-Vital D.A., Gonzalez de Mejia E. Characterization of peptides from common bean protein isolates and their potential to inhibit markers of type-2 diabetes, hypertension and oxidative stress. J. Sci. Food Agric. 2017;97:2401\u20132410. doi: 10.1002/jsfa.8053.", "ArticleIdList": ["10.1002/jsfa.8053", "27664971"]}, {"Citation": "Hatanaka T., Uraji M., Fujita A., Kawakami K. Anti-oxidation activities of rice-derived peptides and their inhibitory effects on dipeptidylpeptidase-IV. Int. J. Pept. Res. Ther. 2015;21:479\u2013485. doi: 10.1007/s10989-015-9478-4.", "ArticleIdList": ["10.1007/s10989-015-9478-4"]}, {"Citation": "Hatanaka T., Inoue Y., Arima J., Kumagai Y., Usuki H., Kawakami K., Kimura M., Mukaihara T. Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food Chem. 2012;134:797\u2013802. doi: 10.1016/j.foodchem.2012.02.183.", "ArticleIdList": ["10.1016/j.foodchem.2012.02.183", "23107693"]}, {"Citation": "Velarde-Salcedo A.J., Barrera-Pacheco A., Lara-Gonzalez S., Montero-Moran G.M., Diaz-Gois A., de Mejia E.G., de la Rosa A.P.B. In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins. Food Chem. 2013;136:758\u2013764. doi: 10.1016/j.foodchem.2012.08.032.", "ArticleIdList": ["10.1016/j.foodchem.2012.08.032", "23122124"]}, {"Citation": "Lammi C., Zanoni C., Arnoldi A., Vistoli G. Peptides Derived from Soy and Lupin Protein as Dipeptidyl-Peptidase IV Inhibitors: In Vitro Biochemical Screening and in Silico Molecular Modeling Study. J. Agric. Food Chem. 2016;64:9601\u20139606. doi: 10.1021/acs.jafc.6b04041.", "ArticleIdList": ["10.1021/acs.jafc.6b04041", "27983830"]}, {"Citation": "Estrada-Salas P.A., Montero-Moran G.M., Martinez-Cuevas P.P., Gonzalez C., de la Rosa A.P.B. Characterization of antidiabetic and antihypertensive properties of canary seed (Phalaris canariensis L.) peptides. J. Agric. Food Chem. 2014;62:427\u2013433. doi: 10.1021/jf404539y.", "ArticleIdList": ["10.1021/jf404539y", "24369818"]}, {"Citation": "Vilcacundo R., Mart\u00ednez-Villaluenga C., Hern\u00e1ndez-Ledesma B. Release of dipeptidyl peptidase IV, \u03b1-amylase and \u03b1-glucosidase inhibitory peptides from quinoa (Chenopodium quinoa Willd.) during in vitro simulated gastrointestinal digestion. J. Funct. Foods. 2017;35:531\u2013539. doi: 10.1016/j.jff.2017.06.024.", "ArticleIdList": ["10.1016/j.jff.2017.06.024"]}, {"Citation": "Huang S.L., Jao C.L., Ho K.P., Hsu K.C. Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides. 2012;35:114\u2013121. doi: 10.1016/j.peptides.2012.03.006.", "ArticleIdList": ["10.1016/j.peptides.2012.03.006", "22450467"]}, {"Citation": "Li-Chan E.C., Hunag S.L., Jao C.L., Ho K.P., Hsu K.C. Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. J. Agric. Food Chem. 2012;60:973\u2013978. doi: 10.1021/jf204720q.", "ArticleIdList": ["10.1021/jf204720q", "22225496"]}, {"Citation": "Harnedy P.A., O\u2019Keeffe M.B., FitzGerald R.J. Purification and identification of dipeptidyl peptidase (DPP) IV inhibitory peptides from the macroalga Palmaria palmata. Food Chem. 2015;172:400\u2013406. doi: 10.1016/j.foodchem.2014.09.083.", "ArticleIdList": ["10.1016/j.foodchem.2014.09.083", "25442570"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "2"}, {"Year": "2021", "Month": "6", "Day": "15"}, {"Year": "2021", "Month": "6", "Day": "16"}, {"Year": "2021", "Month": "7", "Day": "2", "Hour": "1", "Minute": "16"}, {"Year": "2021", "Month": "7", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "3", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "6", "Day": "20"}], "PublicationStatus": "epublish", "ArticleIdList": ["34203048", "PMC8235117", "10.3390/ph14060591", "ph14060591"]}}], "PubmedBookArticle": []}